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Abstract
Background: Allergic contact dermatitis is an inflammatory skin disease that affects a significant proportion of the
population. This disease is caused by an adverse immune response towards chemical haptens, and leads to a
substantial economic burden for society. Current test of sensitizing chemicals rely on animal experimentation. New
legislations on the registration and use of chemicals within pharmaceutical and cosmetic industries have
stimulated significant research efforts to develop alternative, human cell-based assays for the prediction of
sensitization. The aim is to replace animal experiments with in vitro tests displaying a higher predictive power.
Results: We have developed a novel cell-based assay for the prediction of sensitizing chemicals. By analyzing the
transcriptome of the human cell line MUTZ-3 after 24 h stimulation, using 20 different sensitizing chemicals, 20
non-sensitizing chemicals and vehicle controls, we have identified a biomarker signature of 200 genes with potent
discriminatory ability. Using a Support Vector Machine for supervised classification, the prediction performance of
the assay revealed an area under the ROC curve of 0.98. In addition, categorizing the chemicals according to the
LLNA assay, this gene signature could also predict sensitizing potency. The identified markers are involved in
biological pathways with immunological relevant functions, which can shed light on the process of human
sensitization.
Conclusions: A gene signature predicting sensitization, using a human cell line in vitro, has been identified. This
simple and robust cell-based assay has the potential to completely replace or drastically reduce the utilization of
test systems based on experimental animals. Being based on human biology, the assay is proposed to be more
accurate for predicting sensitization in humans, than the traditional animal-based tests.
Background
Allergic contact dermatitis (ACD) is a common inflam-
matory skin disease characterized by eczema and recur-
rent episodes of itching [1]. The disease affects a
significant proportion of the population, with prevalence
rates of 7.2% to 18.6% in Europe [2,3], and the incidence
is increasing due to repeated exposure to sensitizing
chemicals. ACD is a type IV delayed-type hypersensitiv-
ity response caused mainly by reactive T helper 1 (Th1)
and interferon (IFN)g producing CD8
+ T cells, at site of
contact with small chemical haptens in previously
exposed, and immunologically sensitized, individuals [4].
Dendritic cells (DC) in the epidermis initiate the
immune reactions by responding to haptens bound to
self-molecules subsequently activating T cell-mediated
immunity.
The REACH (Registration, Evaluation, and Authoriza-
tion of Chemicals) regulation requires that all new and
existing chemicals within the European Union, involving
approximately 30.000 chemicals, should be tested for
hazardous effects [5]. As the identification of potential
sensitizers currently requires animal testing, the REACH
legislation will have a huge impact on the number of
animals needed for testing. Further, the 7th Amendment
to the Cosmetics Directive posed a ban on animal tests
for the majority of cosmetic ingredients for human use,
to be in effect by 2009, with the exceptions of some
tests by 2013. Thus, development of reliable in vitro
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of sensitizing capacity of chemicals is urgent. To date,
no non-animal replacements are available for identifica-
tion of skin sensitizing chemicals, instead the preferred
assay is the mouse Local Lymph Node Assay (LLNA)
[6], followed by the Guinea pig maximization test
(GPMT) [7]. An in vitro alternative to these animal
models should exhibit improved reliability, accuracy and
importantly correlate to human reactivity.
DCs play key roles in the immune response by brid-
ging the essential connections between innate and adap-
tive immunity. Upon stimulation, they can rapidly
produce large amounts of mediators that affect chemo-
taxis and activation of other cells at the site of inflam-
mation, and can selectively respond to various
pathogens and environmental factors, by fine-tuning the
cellular response through antigen-presentation. Thus,
exploring and utilizing the immunological decision-mak-
ing by DCs during stimulationw i t hs e n s i t i z e r s ,c o u l d
serve as a potent test strategy for the prediction of
sensitization.
Factors that complicate and impede the use of primary
DCs as a test platform include adaptable phenotypes
and specialized functions of different DC subpopula-
tions, in addition to their wide and sparse distribution.
Thus, the development of assays based on the predict-
ability of DC function must rely on alternative cell types
or mimics of in vivo DCs. For this purpose, a cell line
with DC characteristics would be advantageous, as it
constitutes a stable, reproducible and unlimited supply
of cells. MUTZ-3 is an unlimited source of CD34
+ DC
progenitors. Upon differentiation, MUTZ-3 can acquire
phenotypes comparable to immature DCs or Langer-
hans-like DCs [8], present antigens through CD1d,
MHC class I and II and induce specific T-cell prolifera-
tion [9]. Differentiated MUTZ-3 can also display a
mature transcriptional and phenotypic profile upon sti-
mulation with inflammatory cytokines [10].
In this report, we present a novel test principle for the
prediction of skin sensitizers. To simplify the assay pro-
cedures and increase reproducibility, we employed pro-
genitor MUTZ-3 cells, without further differentiation,
and subjected the cells to stimulation with a large panel
of sensitizing chemicals, non-sensitizing chemicals, and
controls. The transcriptional response to chemical sti-
mulation was assessed by genome-wide profiling. From
data analysis, a biomarker signature of 200 transcripts
was identified, which completely separated the response
induced by sensitizing chemicals vs. non-sensitizing che-
micals and the predictive power of the signature was
illustrated, using ROC curves. The biomarker signature
includes transcripts involved in relevant biological path-
ways, such as oxidative stress, DC maturation and cyto-
kine responses, which further could shed light on
molecular interactions involved in the process of sensiti-
zation. In conclusion, we have identified a biomarker
signature with potent predictive power, which we pro-
pose as an in vitro assay for the identification of human
sensitizing chemicals.
Results
The cellular rationale of the in vitro cell culture system
DCs are essential immunoregulatory cells of the
immune system demonstrated by their unique property
to recognize antigen for the initiating of T cell
responses, and their potent regulatory function in skew-
ing immune responses. This makes them obvious targets
for assay development. However, primary DCs constitute
a heterogeneous and minor population of cells not sui-
ted for screening and the choice would be a human DC-
like cell line, with characteristics compared to primary
DCs. Since no leukemic cell line with DC-like properties
has been reported [11], the generation of human DC-
like cell lines relies on available myeloid leukemia cell
lines. MUTZ-3 is a human acute myelomonocytic leuke-
mia cell line with a potent ability to mimic primary
human DCs [11]. Similar to immature primary DCs,
MUTZ-3 progenitors express CD1a, HLA-DR and
CD54, as well as low levels of CD80 and CD86
(Figure 1). The MUTZ-3 population also contains three
subpopulations of CD14
+,C D 3 4
+ and double negative
cells, previously reported to be transitional differentia-
tion steps from a proliferative CD34
+ progenitor into a
Figure 1 Phenotype of MUTZ-3 cells prior to stimulation with
sensitizing and non-sensitizing chemicals. Cell surface expression
levels of CD14, CD1a, CD34, CD54, CD80, CD86 and HLA-DR were
assessed with flow cytometry. Gates were set to exclude debris and
dead cells, and quadrants were established by comparing with
relevant isotype controls. Results are shown from one representative
experiment out of six.
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+ DC precursor [8]. Conse-
quently, constitutively differentiating progenitor MUTZ-
3 cells were used as the basis for a test system.
CD86 surface expression in response to sensitizer
stimulation
CD86 is the most extensively studied biomarker for sen-
sitization to date, using e.g. monocyte derived dendritic
cells (MoDCs) or human cell lines and their progenitors,
such as THP-1, U-937 and KG-1. Thus, as a reference,
cell surface expression of CD86 was measured with flow
cytometry after 24 h stimulation, using 20 sensitizers and
20 non-sensitizers, as well as vehicle controls (Figure 2).
CD86 was significantly up-regulated on cells stimulated
with 2-aminophenol, kathon CG, 2-nitro-1,4-phenylen-
diamine, 2,4-dinitrochlorobenzene, 2-hydroxyethyl acry-
late, cinnamic aldehyde, p-phenylendiamine, resorcinol,
potassium dichromate, and 2-mercaptobenzothiazole.
Hence, an assay based on measurement of a single bio-
marker, such as CD86, would give a sensitivity of 50%
and a specificity of 100%. Consequently, CD86 cannot
classify skin sensitizers, using a system based on MUTZ-
3 cells.
Analysis of the transcriptional profiles in chemically
stimulated MUTZ-3 cells
The genomic expression arrays were then used to test
the same 20 sensitizers and 20 non-sensitizers, in tripli-
cates. The vehicle controls, such as DMSO and distilled
water, were included in twelve replicates. In total, a data
set was generated based on 144 samples. RMA normali-
zation and quality controls of the samples revealed that
the oxazolone and cinnamic aldehyde samples were sig-
nificant outliers and had to be removed, or they would
have dominated the data set prohibiting biomarker iden-
tification (data not shown). In addition, one of the
Figure 2 Changes in CD86 expression following stimulation with sensitizing and non-sensitizing chemicals. Cell surface expression levels
of CD86 were monitored after stimulation with chemicals for 24 h. A). Chemical-induced up regulation of CD86, in terms of changes in
frequency of positive cells, were determined by flow cytometry, as exemplified by the comparison of 2-aminophenol-stimulated cells (right
dotplot) and unstimulated controls (left dot plot). Results are shown from one representative experiment out of three. Gates were set to exclude
debris and dead cells, and quadrants were established by comparing with relevant isotype controls. B) Compilation of frequencies of CD86-
positive cells after 24 h of stimulation. Statistical analysis was performed using Student’s t test. *p < 0.05, # p < 0.01.
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Page 3 of 19replicates of potassium permanganate had to be
r e m o v e dd u et oaf a u l t ya r r a y .T h i sl e f tad a t as e tc o n -
sisting of 137 samples, each with data from measure-
ments of 29,141 transcripts. In order to mine the data
set for information specific for sensitizers vs. non-sensi-
tizers, the software Qlucore Omics Explorer 2.1 was
used, which enable real time principal component
analysis (PCA) analysis. The input genes were at the
same time sorted after desired criteria, i.e. sensitizers
and non-sensitizers, based on ANOVA p-value selection.
Two different ANOVA analyses were performed (Figure
3). First, Figure 3A and 3B show PCA plots based on
1010 transcripts with a p-value of ≤ 2.0 × 10
-6,f r o ma
one-way ANOVA analysis, comparing sensitizing vs.
Figure 3 Principal component analysis of transcripts differentially expressed after chemical stimulation. mRNA levels in MUTZ-3 cells
stimulated for 24 h with 20 sensitizing and 20 non-sensitizing chemicals were assessed with transcriptomics, using Affymetrix Human Gene 1.0
ST arrays. Structures and similarities in the gene expression data set were investigated, using principal component analysis (PCA) in the software
Qlucore. A) PCA of genes differentially expressed in cells stimulated with sensitizing (red) versus non-sensitizing (green) chemicals (1010 genes
identified with one-way ANOVA). B) PCA of genes differentially expressed in cells stimulated with sensitizing versus non-sensitizing chemicals
(1010 genes), but now samples are colored by the compound used for stimulation. C) PCA of genes differentially expressed when comparing
the different stimulations with 2-way ANOVA (1137 genes). Samples are colored according to sensitizing (red) and non-sensitizing (green)
chemicals. D) PCA of genes differentially expressed when comparing the different stimulations with 2-way ANOVA (1137 genes), but now
samples are colored by the compound used for stimulation. P, p-value from ANOVA. Q, p-value corrected for multiple hypothesis testing.
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a clear discrimination can be made between the two
groups, with non-sensitizers forming a condensed cloud
i nt h el o w e rp a r to ft h ef i g u r e( g r e e n ) ,w h i l es e n s i t i z e r s
stretch upwards in various directions (red). However, a
complete separation is not achieved between the two
groups at this level of significance. From Figure 3B, now
colored according to stimulating agent, it is evident that
one or more replicate of glyoxal, eugenol, hexylcinnamic
aldehyde, isoeugenol, resorcinol, penicillin G and ethy-
lendiamine grouped together with the control group. In
addition, one replicate or more of the non-sensitizers
tween 80, octanoic acid and phenol grouped closely with
the sensitizers. Secondly, Figure 3C and 3D show PCA
plots based on 1137 genes, with p-values ≤ 7.0 × 10
-21,
from a multi-group ANOVA analysis, comparing each
individual stimulation. Identifying this large number of
genes at this level of significance provided strong indica-
tions of the power in the data set. In Figure 3D, it is clear
that the replicates group together, indicating high quality
data. The triplicate samples of potassium dichromate
have a discrete profile, which demonstrate a substantial
impact of the cells compared to non-sensitizers. Further-
more, 2-hydroxyethyl acrylate, 2-aminophenol, kathon
CG, formaldehyde, 2-nitro-1,4-phenylendiamine, 2,4-
dinitrochlorobenzoic acid, p-phenylendiamine, 2-mercap-
tobenzothiazole, cinnamic alcohol and resorcinol have
replicates that group together, separate from the negative
group. Still, as can be seen in Figure 3C as well as in 3A,
complete separation is not achieved with neither of the
gene signatures of 1010 and 1137 genes both selected on
p-values.
Backward elimination identifies genes with the most
discriminatory power
Even though the data set contains genes with p-values
down to 1 × 10
-17, lowering the p-value cutoff did not
achieve complete separation between sensitizers and
non-sensitizers. Gene signatures entirely selected on p-
values does not provide the best possible predictive
power, since the information is per se not orthogonal.
To further reduce the number of transcripts for a pre-
dictive biomarker signature, we employed an algorithm
for backward elimination (Figure 4A). The algorithm
Figure 4 Identification and PCA analysis of Prediction Signature. A) The number of differentially expressed significant genes in cells
stimulated with sensitizing versus non-sensitizing chemicals (1010 genes) was reduced, using Backward Elimination. The lowest KLD is observed
after elimination of 810 analytes, referred to as the Breakpoint. The remaining 200 genes are considered to be the top predictors in the data set,
and are termed Prediction Signature. B) Complete separation between sensitizers (red) and non-sensitizers (green) is observed with PCA of the
Prediction Signature. C) Same PCA as in B, now with samples colored according to their potency in LLNA.
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only the impact of genes individually, but how they per-
form collectively with the entire selected gene signature.
For each gene eliminated, the Kullback-Leibler diver-
g e n c e( K L D )v a l u ei sl o w e r e d ,u n t i lab r e a k p o i n ti s
reached, at which point 200 genes remained. Continuing
eliminating genes at this point causes the KLD to rise
again, indicating that information is being lost (Figure
4A). Therefore, the 200 genes with lowest KLD value
were selected for further analysis. PCA of the 200 ana-
lytes now revealed that they have the ability to comple-
tely separate sensitizers from non-sensitizers, indicating
that these transcripts can be used as predictors for sen-
sitizing properties of unknown samples (Figure 4B).
Importantly, by coloring the samples in the PCA by
their potency, according to LLNA, it is clear that
potency can also be predicted (Figure 4C), as extreme
and strong sensitizers tend to group further from the
non-sensitizers, while moderate and extreme sensitizers
group closer to non-sensitizers. The 200 genes are
termed the “Prediction Signature” and their identities
are listed in Table 1. In addition, the transcriptional
profiles of the differentially expressed genes are pre-
sented in a heatmap (Figure 5).
Interrogation of the analysis used to identify the
Prediction Signature
To validate the predictive power of our signature, we
used a machine learning method called the Support
Vector Machine (SVM) [12], which maps the data from
a training set in space in order to maximize the separa-
tion of gene expression induced by sensitizing and non-
sensitizing chemicals. As training set, 70% of the data
set was selected randomly and the entire selection pro-
cess was repeated. Starting with 29,141 transcripts, the
signature was reduced to 200 transcripts, termed “Test
Gene Signature”, using ANOVA filtering and backward
elimination, as described above. The remaining 30% of
the data set was used to test each signature. The parti-
tioning of the data set into subsets of 70% training data
set and 30% test data set was done in a stratified ran-
dom manner, while maintaining the relation of sensiti-
zers and non-sensitizers. Thereafter, the Test Gene
Signature was used to train an SVM model with the
training set, and the predictive power of the model was
assessed with the test set. This entire process was iter-
ated 20 times. The frequency by which each gene in the
Prediction Signature was included in the Test Gene Sig-
natures is reported in table 1. Figure 6A shows a PCA
plot based on the Test Gene Signature from one repre-
sentative iteration. Clearly, the separation between sensi-
tizers and non-sensitizers resembles the one observed
for the Prediction Signature in Figure 4B. In Figure 6A,
the samples of the sensitizing and non-sensitizing
chemicals in the test set have been colored dark red and
dark green respectively, indicating that they are not con-
tributing to the principal components of the plot, but
are merely plotted based on their expression values of
the selected Test Gene Signature. As can be seen, sensi-
tizers from the test set group with sensitizers from the
training set, while non-sensitizers from the test set
group with non-sensitizers from the training set. The
final outcome of the SVM training and validation can
be seen in Figure 6B, where the areas under the ROC
curve are plotted for each iteration. The average area
under the ROC curve of 0.98 confirms the ability to dis-
criminate sensitizers from control samples. Based on
this average, the estimated prediction performance of
the assay reveals an accuracy of 99%, sensitivity of 99%
and specificity of 99%. While this experiment does not
validate the prediction power of the Prediction Signature
per se, it does indeed validate the method by which it
has been selected, supporting the claim that the Predic-
tion Signature is capable of accurately predicting sensi-
tizing properties of unknown samples.
Interactome, molecular functions and canonical pathways
involving the Prediction Signature
Using Ingenuity Pathways Analysis (IPA, Ingenuity Sys-
tems Inc.), 184 of the 200 molecules in the signature
were characterized with regard to the interactome,
known functions and (canonical) pathways. The remain-
ing 16 molecules could not be mapped to any unique
IPA entries. The dominating functions identified were
small molecule biochemistry (39 molecules), cell death
(33), lipid metabolism (25), hematological system devel-
opment (18), cell cycle (18), molecular transport (17),
cellular growth and proliferation (16), and carbohydrate
metabolism (15) (Table 2).
Pathways possibly invoked by the molecules in the sig-
nature were also investigated using IPA. Those most
highly populated involved NRF2-mediated oxidative
response (10), xenobiotic metabolism signaling (8), pro-
tein ubiquitination pathway (7), LPS/IL-1 mediated inhi-
bition of RXR function (6), aryl hydrocarbon receptor
signaling (6) and protein kinase A signaling (6). These
pathways are known to take part in reactions provoked
by foreign substances, xenobiotics, which supports a
relevant biology behind the genomic signature.
Discussion
Allergic contact dermatitis (ACD) is an inflammatory
skin disease caused by an adaptive immune response to
normally innocuous chemicals [13]. Small molecular
weight chemicals, so-called haptens, can bind self-pro-
teins in the skin, which enables internalization of the
protein-bound allergenic chemical by skin dendritic cell
(DC). DCs, under the influence of the local
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Gene Title Gene Symbol Entrez Gene ID Affymetrix
HuGene 1.0 ST
ID
Validation Call
frequency (%)
4-aminobutyrate aminotransferase ABAT 18 7993126 30
abhydrolase domain containing 5 ABHD5 51099 8079153 85
alkaline ceramidase 2 ACER2 340485 8154563 95
ATP citrate lyase ACLY 47 8015460 85
actin-related protein 10 homolog (S. cerevisiae) ACTR10 55860 7974587 75
ADAM metallopeptidase domain 20 ADAM20 8748 7979927 35
aldehyde dehydrogenase 18 fam., member A1 ALDH18A1 5832 7935230 75
aldehyde dehydrogenase 1 fam., member B1 ALDH1B1 219 8155327 70
anaphase promoting complex subunit 1 ANAPC1 64682 8043349 55
anaphase promoting complex subunit 5 ANAPC5 51433 7967149 25
ankyrin repeat, fam. A (RFXANK-like), 2 ANKRA2 57763 8112596 100
ADP-ribosylation factor GTPase activating protein 3 ARFGAP3 26286 8076515 55
Rho GTPase activating protein 9 ARHGAP9 64333 7964436 75
ankyrin repeat and SOCS box-containing 7 ASB7 140460 7986433 65
ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit d1//ATPase, H+
transporting, lysosomal 38 kDa, V0 subunit d1
ATP6V0D1//
ATP6V0D1
9114//9114 8002041 10
ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e1 ATP6V0E1 8992 8110022 75
ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H ATP6V1H 51606 8150797 100
B-cell CLL/lymphoma 7A BCL7A 605 7959354 85
bridging integrator 2 BIN2 51411 7963289 80
bleomycin hydrolase BLMH 642 8014008 15
brix domain containing 1//ribosome production factor 2 homolog (S.
cerevisiae)
BXDC1//RPF2 84154//84154 8062211 40
chromosome 11 open reading frame 61 C11orf61 79684 7952445 55
chromosome 11 open reading frame 67//integrator complex subunit 4 C11orf67//INTS4 28971//92105 7942783 50
chromosome 12 open reading frame 57 C12orf57 113246 7953564 40
chromosome 13 open reading frame 18 C13orf18 80183 7971486 50
chromosome 15 open reading frame 24 C15orf24 56851 7987172 50
chromosome 19 open reading frame 46//alkB, alkylation repair homolog
6 (E. coli)
C19orf46//
ALKBH6
163183//84964 8036242 30
chromosome 19 open reading frame 54 C19orf54 284325 8036956 95
chromosome 1 open reading frame 174 C1orf174 339448 7911897 40
chromosome 1 open reading frame 183 C1orf183 55924 7918552 85
chromosome 20 open reading frame 111 C20orf111 51526 8066402 65
chromosome 20 open reading frame 24 C20orf24 55969 8062326 20
chromosome 3 open reading frame 62//ubiquitin specific peptidase 4
(proto-oncogene)
C3orf62//USP4 375341//7375 8087374 40
chromosome 9 open reading frame 89 C9orf89 84270 8156404 100
coactivator-associated arginine methyltransferase 1 CARM1 10498 8025766 60
CD33 molecule CD33 945 8030804 45
CD86 molecule CD86 942 8082035 45
CD93 molecule CD93 22918 8065359 50
cytochrome c oxidase subunit VIIa polypeptide 2 like COX7A2L 9167 8051777 45
corticotropin releasing hormone binding protein CRHBP 1393 8106418 45
chondroitin sulfate N-acetylgalactosaminyltransferase 2 CSGALNACT2 55454 7927146 90
cytochrome P450, fam. 51, subfam. A, polypeptide 1 CYP51A1 1595 8140864 85
DDRGK domain containing 1 DDRGK1 65992 8064601 60
DEAD (Asp-Glu-Ala-As) box polypeptide 19A DDX19A 55308 7997059 95
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 DDX21 9188 7927936 60
24-dehydrocholesterol reductase DHCR24 1718 7916432 100
7-dehydrocholesterol reductase DHCR7 1717 7950067 80
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DEAH (Asp-Glu-Ala-His) box polypeptide 33 DHX33 56919 8011861 100
DnaJ (Hsp40) homolog, subfam. B, member 4 DNAJB4 11080 7902512 100
DnaJ (Hsp40) homolog, subfam. B, member 9 DNAJB9 4189 8135480 25
DnaJ (Hsp40) homolog, subfam. C, member 5 DNAJC5 80331 8064208 10
DnaJ (Hsp40) homolog, subfam. C, member 9 DNAJC9 23234 7934320 55
DNA-damage regulated autophagy modulator 2//choline/ethanolamine
phosphotransferase 1
DRAM2//CEPT1 128338//10390 7918474 100
D-tyrosyl-tRNA deacylase 1 homolog (S. cerevisiae) DTD1 92675 8061211 45
ER degradation enhancer, mannosidase alpha-like 2 EDEM2 55741 8065855 80
ecotropic viral integration site 2B EVI2B 2124 8014063 60
fam. with sequence similarity 36, member A//non-protein coding RNA
201
FAM36A//
NCRNA00201
116228//284702 7911085 15
fam. with sequence similarity 86, member A FAM86A 196483 7999304 25
Fas (TNF receptor superfam., member 6) FAS 355 7929032 70
fatty acid synthase FASN 2194 8019392 100
F-box protein 10//translocase of outer mitochondrial membrane 5
homolog (yeast)
FBXO10//TOMM5 26267//401505 8161229 40
MGC44478 FDPSL2A 619190 8140443 55
ferredoxin reductase FDXR 2232 8018236 40
forkhead box O4 FOXO4 4303 8168205 80
ferritin, heavy polypeptide-like 5 FTHL5 2509 8126948 95
fucosidase, alpha-L- 2, plasma FUCA2 2519 8129974 20
growth arrest-specific 2 like 3 GAS2L3 283431 7957850 70
ganglioside induced differentiation associated protein 2 GDAP2 54834 7918955 80
growth differentiation factor 11 GDF11 10220 7956026 65
glutaredoxin (thioltransferase) GLRX 2745 8113214 90
guanine nucleotide binding protein-like 3 (nucleolar)-like GNL3L 54552 8167797 85
glucosamine-phosphate N-acetyltransferase 1 GNPNAT1 64841 7979196 90
glutathione reductase GSR 2936 8150112 40
GTF2I repeat domain containing 2//GTF2I repeat domain containing 2B GTF2IRD2//
GTF2IRD2B
84163//389524 8133549 and
8140170
50 and 30
general transcription factor IIIC, polypeptide 2, beta 110 kDa GTF3C2 2976 8051075 55
HMG-box transcription factor 1//component of oligomeric golgi complex
5
HBP1//COG5 26959//10466 8135392 65
histone cluster 1, H1c HIST1H1C 3006 8124397 45
histone cluster 1, H1e HIST1H1E 3008 8117377 95
histone cluster 1, H2ae HIST1H2AE 3012 8117408 45
histone cluster 1, H2be HIST1H2BE 8344 8117389 15
histone cluster 1, H3g HIST1H3G 8355 8124440 35
histone cluster 1, H3j HIST1H3J 8356 8124537 60
histone cluster 1, H4a HIST1H4A 8359 8117334 10
histone cluster 2, H2ac//histone cluster 2, H2aa3//histone cluster 2, H2aa4 HIST-2H2AC//
2H2AA3//2H2AA4
8338//8337//
723790
7905079 and
7919619
75 and 75
histone cluster 2, H2bf//histone cluster 2, H2be//histone cluster 2, H2ba HIST-2H2BF//
2H2BE//2H2BA
440689//8349//
337875
7919606 50
high-mobility group box 3 HMGB3 3149 8170468 5
3-hydroxy-3-methylglutaryl-Coenzyme A reductase//3-hydroxy-3-
methylglutaryl-CoA reductase
HMGCR//HMGCR 3156//3156 8106280 90
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)//3-hydroxy-
3-methylglutaryl-CoA synthase 1 (soluble)
HMGCS1//
HMGCS1
3157//3157 8111941 80
heme oxygenase (decycling) 1 HMOX1 3162 8072678 10
heterogeneous nuclear ribonucleoprotein L HNRNPL 3191 8036613 30
insulin receptor substrate 2 IRS2 8660 7972745 35
iron-sulfur cluster scaffold homolog (E. coli) ISCU 23479 7958414 100
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interferon stimulated exonuclease gene 20 kDa-like 2 ISG20L2 81875 7921110 45
potassium voltage-gated channel, Isk-related fam., member 3 KCNE3 10008 7950409 25
keratinocyte growth factor-like protein 1//fibroblast growth factor 7
(keratinocyte growth factor)//keratinocyte growth factor-like protein 2//
hypothetical protein FLJ20444
KGFLP1//FGF7//
KGFLP2//
FLJ20444
387628//2252//
654466//403323
8155530 70
lysophosphatidic acid receptor 1 LPAR1 1902 8163257 10
leucine-rich PPR-motif containing LRPPRC 10128 8051882 65
lymphocyte antigen 96 LY96 23643 8146934 35
mitogen-activated protein kinase kinase 1//small nuclear RNA activating
complex, polypeptide 5, 19 kDa
MAP2K1//SNAPC5 5604//10302 7984319 30
mitogen-activated protein kinase 13 MAPK13 5603 8119016 60
methyltransferase like 2A METTL2A 339175 8009008 45
microsomal glutathione S-transferase 3 MGST3 4259 7906978 70
mitochondrial ribosomal protein L30 MRPL30 51263 8043848 30
mitochondrial ribosomal protein L4 MRPL4 51073 8025586 40
mitochondrial ribosomal protein S17//glioblastoma amplified sequence//
zinc finger protein 713
MRPS17//GBAS//
ZNF713
51373//2631//
349075
8132922 60
mitochondrial poly(A) polymerase//golgi autoantigen, golgin subfam. a, 6
pseudogene
MTPAP//
LOC729668
55149//729668 7932834 45
5-methyltetrahydrofolate-homocysteine methyltransferase MTR 4548 7910752 15
neighbor of BRCA1 gene 1 NBR1 4077 8007471 20
nuclear import 7 homolog (S. cerevisiae) NIP7 51388 7996934 75
NLR fam., pyrin domain containing 12 NLRP12 91662 8039096 35
nucleolar protein fam. 6 (RNA-associated) NOL6 65083 8160682 95
NAD(P)H dehydrogenase, quinone 1 NQO1 1728 8002303 45
nuclear receptor binding protein 1 NRBP1 29959 8040927 20
nucleotide binding protein-like NUBPL 80224 7973826 10
nudix (nucleoside diphosphate linked moiety X)-type motif 14 NUDT14 256281 7981566 35
nuclear fragile × mental retardation protein interacting protein 1 NUFIP1 26747 7971361 60
nucleoporin 153 kDa NUP153 9972 8124059 25
olfactory receptor, fam. 5, subfam. B, member 21 OR5B21 219968 7948330 50
PAS domain containing serine/threonine kinase PASK 23178 8060205 55
PRKC, apoptosis, WT1, regulator PAWR 5074 7965112 30
PDGFA associated protein 1 PDAP1 11333 8141273 35
phosphodiesterase 1B, calmodulin-dependent PDE1B 5153 7955943 85
phosphoribosylformylglycinamidine synthase PFAS 5198 8004804 60
pleckstrin homology-like domain, fam. A, member 3 PHLDA3 23612 7923372 75
phosphoinositide-3-kinase adaptor protein 1 PIK3AP1 118788 7935337 20
PTEN induced putative kinase 1 PINK1 65018 7898663 70
phosphomannomutase 2 PMM2 5373 7993148 65
partner of NOB1 homolog (S. cerevisiae) PNO1 56902 8042381 40
polymerase (RNA) II (DNA directed) polypeptide E, 25 kDa POLR2E 5434 8032149 80
polymerase (RNA) III (DNA directed) polypeptide E (80 kD) POLR3E 55718 7993973 30
protein phosphatase 1D magnesium-dependent, delta isoform//protein
phosphatase, Mg2+/Mn2+ dependent, 1D
PPM1D//PPM1D 8493//8493 8008922 80
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 PREX1 57580 8066848 100
proline-serine-threonine phosphatase interacting protein 1 PSTPIP1 9051 7985099 95
prothymosin, alpha PTMA 5757 7954006 and
7961022
20 and 15
RAB33B, member RAS oncogene fam. RAB33B 83452 8097507 40
renin binding protein RENBP 5973 8175933 65
replication factor C (activator 1) 2, 40 kDa RFC2 5982 8140151 30
ribonuclease H1 RNASEH1 246243 8050079 90
ring finger protein 146 RNF146 81847 8121927 50
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ring finger protein 24 RNF24 11237 8064766 100
ring finger protein 26 RNF26 79102 7944510 95
ribosomal protein SA//small nucleolar RNA, H/ACA box 62 RPSA//SNORA62 3921//6044 8078918 75
RNA pseudouridylate synthase domain containing 2 RPUSD2 27079 7982753 45
ribosomal RNA processing 12 homolog (S. cerevisiae) RRP12 23223 7935425 75
retinoid × receptor, alpha RXRA 6256 8159127 5
scavenger receptor class B, member 2 SCARB2 950 8101158 70
SERPINE1 mRNA binding protein 1 SERBP1 26135 7916836 95
splicing factor proline/glutamine-rich (polypyrimidine tract binding
protein associated)//splicing factor proline/glutamine-rich
SFPQ//SFPQ 6421//6421 7914791 40
solute carrier fam. 25, member 32//DDB1 and CUL4 associated factor 13 SLC25A32//
DCAF13
81034//25879 8152255 100
solute carrier fam. 35, member B3 SLC35B3 51000 8123825 40
solute carrier fam. 37 (glucose-6-phosphate transporter), member 4 SLC37A4 2542 7952132 55
solute carrier fam. 5 (sodium-dependent vitamin transporter), member 6 SLC5A6 8884 8051030 95
sphingomyelin phosphodiesterase 4, neutral membrane (neutral
sphingomyelinase-3)
SMPD4 55627 8055183 40
small nucleolar RNA host gene 1 (non-protein coding)//small nucleolar
RNA, C/D box 26
SNHG1//
SNORD26
23642//9302 7948908 20
small nucleolar RNA host gene 12 (non-protein coding) SNHG12 85028 7914202 10
small nucleolar RNA, H/ACA box 45 SNORA45 677826 7938293 25
sorting nexin fam. member 27 SNX27 81609 7905444 35
spinster homolog 2 (Drosophila)//MYB binding protein (P160) 1a SPNS2//MYBBP1A 124976//10514 8011640 45
sprouty homolog 2 (Drosophila) SPRY2 10253 7972217 75
squalene epoxidase SQLE 6713 8148280 95
sterol regulatory element binding transcription factor 2 SREBF2 6721 8073522 45
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 ST3GAL6 10402 8081219 100
serine/threonine kinase 17b STK17B 9262 8057887 90
transmembrane anterior posterior transformation 1 TAPT1 202018 8099506 65
taste receptor, type 2, member 5 TAS2R5 54429 8136647 40
tubulin folding cofactor E-like TBCEL 219899 7944623 55
tectonic fam. member 2 TCTN2 79867 7959638 40
toll-like receptor 6 TLR6 10333 8099841 30
transmembrane protein 150B TMEM150B 284417 8039453 25
transmembrane protein 55A TMEM55A 55529 8151756 90
transmembrane protein 59 TMEM59 9528 7916372 90
transmembrane protein 97 TMEM97 27346 8005839 95
tumor necrosis factor receptor superfam., member 10c, decoy without an
intracellular domain
TNFRSF10C 8794 8145244 75
translocase of outer mitochondrial membrane 34 TOMM34 10953 8066461 35
translocase of outer mitochondrial membrane 40 homolog (yeast) TOMM40 10452 8029521 40
tumor protein p53 inducible protein 3 TP53I3 9540 8050702 30
tumor protein p53 inducible nuclear protein 1 TP53INP1 94241 8151890 100
twinfilin, actin-binding protein, homolog 2 (Drosophila)//toll-like receptor
9
TWF2//TLR9 11344//54106 8087860 65
thioredoxin reductase 1 TXNRD1 7296 7958174 55
ubiquitin-fold modifier conjugating enzyme 1 UFC1 51506 7906662 95
ubiquitin specific peptidase 10 USP10 9100 7997633 30
vesicle-associated membrane protein 3 (cellubrevin) VAMP3 9341 7897370 40
valyl-tRNA synthetase VARS 7407 8125091 and
8178609
10 and 10
vacuolar protein sorting 37 homolog A (S. cerevisiae) VPS37A 137492 8144774 60
zinc finger protein 211 ZNF211 10520 8031792 45
zinc finger protein 223 ZNF223 7766 8029360 65
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Page 10 of 19microenvironment, process the protein-hapten complex,
migrate to the local lymph nodes and activate naïve T
cells. The initiation and development of allergen-specific
responses, mainly effector CD8+ T cells and Th1 cells,
and production of immunoregulatory proteins, are hall-
marks of the immune activation observed in ACD. ACD
is also the most common manifestation of immunotoxi-
city observed in humans [13] and hundreds of chemicals
have been shown to cause sensitization in skin [14]. The
driving factors and molecular mechanisms involved in
sensitization are still unknown even though intense
research efforts have been carried out to characterize
the immunological responses towards allergenic chemi-
cals. The REACH legislation requires that all chemicals
produced over 1 ton/year are tested for hazardous
properties such as toxicity and allergenicity [5], which
increase the demand for accurate assays with predictive
power for hazard identification. Additionally, the 7th
Amendment to the Cosmetics Directive (76/768/EEC)
poses a complete ban on using animal experimentation
for testing cosmetic ingredients by 2013 if a scientifically
reliable method is available. Thus, there is a significant
need for predictive test methods that are based on
human cells. Today, the identification of potential
human sensitizers relies on animal experimentation, in
particular the murine local lymph node assay (LLNA)
[6]. The LLNA is based upon measurements of prolif-
eration induced in draining lymph nodes of mice after
chemical exposure [15]. Chemicals are defined as sensi-
tizers if they provoke a three-fold increase in prolifera-
tion compared to control, and the amount of chemical
required for the increase is the EC3 value. Thus, the
LLNA can also be used to categorize the chemicals
based on sensitization potency. However, LLNA is,
besides the obvious ethical implications, also time con-
suming and expensive. Human sensitization data often
stem from human maximization tests (HMT) [16] and
h u m a np a t c ht e s t s( H P T ) .I na ne x t e n s i v er e p o r tf r o m
the Interagency Coordinating Committee on the Valida-
tion of Alternative Methods (ICCVAM), the perfor-
mance characteristics of LLNA were compared to other
available animal-based methods and human sensitization
data (HMT and HPT) [17]. The LLNA performance in
comparison to human data (74 assessments) revealed an
accuracy of 72%, a sensitivity of 72% and a specificity of
67%.
Various human cell lines and primary cells involved in
sensitization have been evaluated as predictive test sys-
tem, such as epithelial cells, dendritic cells and T cells,
however, no validated test assay is currently available.
THP-1, U937, KG-1 and MUTZ-3, naive or differen-
tiated, are among the human myeloid cell lines most
extensively evaluated as platforms for DC-based in vitro
assays, as reviewed in [18]. These cells are easy to grow
Table 1 Prediction Signature (Continued)
zinc finger protein 561 ZNF561 93134 8033795 60
zinc finger protein 79 ZNF79 7633 8158022 100
— —— 7910385 40
— —— 7946567 15
— —— 7966223 45
— —— 7979694 40
— —— 8130495 30
— —— 8180237 60
— —— 8180268 85
— —— 8180417 85
The table shows the biomarker genes found by t-test and Backward Elimination. Genes were annotated, using the NetAffx database from Affymetrix (http://www.
affymetrix.com, Santa Clara USA). When found, the Entrez Gene ID http://www.ncbi.nlm.nih.gov/gene was chosen as the gene identifier. The validation call
frequency (%) is the occurrence of each gene in the 20 Test Gene Signatures obtained in the validation step.
Figure 5 Transcriptional profiles of sensitizers and non-
sensitizers. Hierarchical clustering of the genes in the Prediction
Signature. Samples are grouped as sensitizer or non-sensitizer, and
all replicates are included. Each row represents one gene, which is
scaled to have a mean of zero and standard deviation of one, with
colors representing the number of standard deviations from the
mean.
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Page 11 of 19and enable standardization of protocols. U937 and THP-
1 are currently being evaluated in pre-validation stage
for prediction of skin sensitization. The Human Cell
Line Activation Test (hCLAT) is based upon analysis of
CD86 and/or CD54 expression on THP-1 cells after
chemical stimulation [19,20]. The Myeloid U937 Skin
Sensitization Test (MUSST) also involves analysis of
CD86 [21]. These assays are thus very limited in
Figure 6 Validation of selection procedure of Prediction Signature. The method by which the Prediction Signature was constructed was
validated by repeating the process on 70% randomly selected data (training set). The remaining 30% of data was used as a test set for signature
validation. The process was repeated for 20 iterations. A) A representative PCA of one of the 20 iterations, which demonstrates that the Test
Gene Signature can separate skin sensitizers from non-sensitizers. Only the samples of the 70% training set, displayed in bright colors, were used
to build the space of the first three principal components. The test set samples, displayed in dark colors, were plotted into this space based on
expression levels of the analytes in the Test Gene Signature. B) An SVM was trained on the 70% training set, and validated with the 30% test set.
The areas under the ROC curve from 20 such randomizations are plotted, yielding an average AUC value of 0.98. This indicated that the
classification of samples in the test set was correct.
Table 2 Dominating functions of the Prediction signature
Function Number of
molecules from
signature
Molecule names Most prominent sub functions
small molecule
biochemistry
39 ABHD5, ACLY, ALDH18A1, BLMH, CD86, CSGALNACT2, CYP51A1,
DHCR24, DHCR7, DNAJC5, FAS, FASN, FDXR, FOXO4, GLRX, GNPNAT1,
HMGCR, HMOX1, IRS2, LPAR1, LY96, MGST3, MTR, NQO1, PASK, PDE1B,
PINK1, PMM2, RENBP, RXRA, SLC25A32, SLC37A4, SLC5A6, SMPD4, SQLE,
SREBF2, ST3GAL6, TLR6, TMEM55A
Metabolism (24), biosynthesis
(15), modification (12), synthesis
(11)
cell death 33 CD33, DDX19A, DHCR24, DNAJB9, DNAJC5, FAS, FASN, FDXR, FOXO4,
GLRX, GNPNAT1, GSR, HIST1H1C, HMGB3, HMOX1, IRS2, LPAR1, MAP2K1,
MAPK13, NQO1, PAWR, PDE1B, PHLDA3, PINK1, PPM1D, RXRA, SERBP1,
SPRY2, STK17B, TLR6, TNFRSF10C, TP53INP1, TXNRD1
Apoptosis (30), cell death (13)
lipid metabolism 25 ABHD5, ACLY, CYP51A1, DHCR24, DHCR7, FAS, FASN, FDXR, FOXO4,
HMGCR, HMOX1, IRS2, LPAR1, LY96, MGST3, PASK, RENBP, RXRA,
SLC37A4, SMPD4, SQLE, SREBF2, ST3GAL6, TLR6, TMEM55A
Metabolism (18),
synthesis (11), modification (11)
hematological
system
development
18 CARM1, CD33, CD86, FAS, FOXO4, HMGB3, HMGCR, HMOX1, IRS2, LY96,
NBR1, NQO1, PAWR, PIK3AP1, PPM1D, STK17B, TP53INP1, VAMP3
Proliferation (10),
quantity (7)
cell cycle 18 ABHD5, ANAPC5, DNAJB4, DTD1, FAS, FASN, FOXO4, GDF11, HBP1,
HMOX1, IRS2, MAP2K1, PAWR, PPM1D, RXRA, SFPQ, SPRY2, TP53INP1
Cell cycle progression (13), G2
phase (5)
molecular
transport
17 ABHD5, DNAJC5, FAS, FOXO4, HMOX1, LPAR1, MTR, NQO1, PASK, PINK1,
RENBP, RXRA, SLC25A32, SLC37A4, SLC5A6, SREBF2, TLR6
Accumulation (9), quantity (5)
cellular growth
and proliferation
16 CD33, CD86, FAS, GNPNAT1, HMOX1, IRS2, LPAR1, LY96, MAP2K1, PAWR,
PIK3AP1, PPM1D, RXRA, SPRY2, STK17B, TP53INP1
Proliferation (16), growth (4)
carbohydrate
metabolism
15 ABHD5, ACLY, CSGALNACT2, FAS, FASN, FUCA2, GNPNAT1, IRS2, LY96,
NQO1, PMM2, RENBP, SLC37A4, ST3GAL6, TMEM55A
Metabolism (9), biosynthesis (5)
Dominating functions in the molecular signature. 184 of the 200 molecules were functionally investigated, using IPA. Only functions populated by 15 or more
genes were included in the present study.
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Page 12 of 19readout. As CD86 is among the markers most exten-
sively studied, we evaluated the expression level of this
marker in our assay. We demonstrated its relevance but
also its insufficient predictive power (Figure 2), since
only 10 out of 20 sensitizing chemicals induced a signifi-
cant up regulation of CD86. Various other single bio-
markers have been suggested to be up regulated upon
stimulation with sensitizing chemicals, such as CD40,
CD80, CD54, CXCL8, IL-1b,M I P - 1 b,p 3 8M A P K ,a s
reviewed in [18], yet single-handedly, none of them have
enough predictive power to discriminate between sensi-
tizing and non-sensitizing chemicals. The analysis of
biomarker signatures, i.e. combination of biomarkers,
has been shown to be superior in molecular diagnostic
of cancer and superior to any single biomarker. Conse-
quently, we therefore utilized the power of global tran-
scriptomics and screened the gene regulation induced
by a large set of well-defined chemicals and controls in
search of predictive biomarker combinations.
The large number of differentially expressed genes in
MUTZ-3 cells stimulated with sensitizing chemicals vs.
non-sensitizing controls revealed that MUTZ-3 indeed
had a capacity to differentiate between these two groups.
Efforts have previously been done to create assays based
on genome analysis in various cell systems, such as e.g.
CD34
+-progenitor cells-derived DCs [22-24]. While such
assays might provide in vivo like environments, primary
cells are not well suited for a high-throughput format
considering both donor-dependent variations as well as
ethical aspect of such cell sources. Furthermore, pre-
vious efforts within in vitro assay development for sensi-
tization that rely on full genome analysis have used a
limited set of testing compounds.
The present study utilized in all 40 compounds and
efforts were made to divide these compounds into two
subsets, for training and testing respectively. While
these experiments have resulted in successful predic-
tions (data not shown), it is our experience that sensitiz-
ing compounds differ greatly in their induced gene
expression profile, as can be seen in Figure 3D. In this
perspective, we strived to include as many training com-
pounds as possible when identifying our Prediction Sig-
nature, and did not exclude any compounds for
validation. Instead, we validated the method by which
the Prediction Signature was identified, by subdividing
the samples into training and test sets at random, using
unseen data for validation, to avoid overfitting. At pre-
sent, the Prediction Signature consists of 200 transcripts,
based on Figure 4A. Continuing the elimination process
beyond 200 transcripts causes loss of information, as
seen by the rise of KLD. Experiments have shown that
correct classifications are possible even with further
reduced signatures, down to 11 genes (data not shown).
A reduction of signature size could be assessed in
conjunction with validation of the assay, using untested
positive and negative compounds in a new test set. By
reducing the signature size at this point, the risk of bias-
ing the signature towards this data set increases, making
it harder to correctly classify unknown samples. Addi-
tional test compounds will also serve to assess the fre-
quency of extreme transcriptional profile outliers, such
as Oxazolone and Cinnamic aldehyde, which had to be
removed from the analysis performed in this study. A
number of reasons may be attributed to the fact that
these compounds were not compatible with the assay,
such as solubility in the cell media or extreme toxic
effects. In those cases, other in vitro alternatives may
complement this assay, so that the safety assessment of
chemicals for sensitization includes a battery of in vitro
assays. Naturally, an additional data set with blinded
compounds is essential to validate whether the assay
truly performs as estimated by the random subdivisions
into training and test sets.
Of note, our Prediction Signature is able to predict
the potency of sensitizing compounds, as defined by
the LLNA (Figure 4C). However, the potency predicted
by LLNA and that of our classifier do not match for
all samples. Notably, the moderate sensitizer 2-hydro-
xyethyl acrylate showed resemblance to strong and
extreme sensitizers with respect to gene expression
profile. Similarly, the moderates e n s i t i z e r se t h y l e n d i a -
mine, hexylcinnamic aldehyde, and glyoxal grouped
together with weak sensitizers. These findings support
the fact that sensitizing potency, as defined, may need
revising.
By studying the identity of the transcripts and their
involvement in intracellular signaling pathways, we were
also able to confirm the biological relevance of the Pre-
diction Signature. Using IPA, we found that the most
highly populated pathways were nuclear factor-erythroid
2-related factor 2 (NRF2) mediated oxidative response,
xenobiotic metabolism signaling, protein ubiquitination
pathway, LPS/IL-1 mediated inhibition of Retinoic X
receptor (RXR) function, aryl hydrocarbon receptor
(AHR) signaling, and protein kinase A (PKA) signaling.
These pathways are all known to take part in reactions
provoked by xenobiotics, and several were associated
with oxidative stress. Furthermore, Toll-like receptor
(TLR) signaling is among the top pathways found in
IPA. Recent studies on assay development for prediction
of sensitization in vitro have to a large extent focused
on how danger signals are provided to antigen-present-
ing cells, inducing pro-inflammatory cytokines and che-
mokines, as well as co-stimulatory molecules needed for
a specific T-cell response. We hypothesize that these
signals are provided through the innate immune
responses, in analogy with infections, as reviewed in
[25].
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NRF2 signaling. This is a pathway activated by Reactive
Oxygen Species (ROS), and is a defense mechanism to
xenobiotics and response to cellular stress. In the resting
cell, NRF2 is bound by kelch-like ECH-associated pro-
tein 1 (KEAP1) and located in the cytosol. In the
response to ROS activity, KEAP1 is targeted for ubiqui-
tination and protesomal degradation, resulting in the
translocation of NRF2 to the nucleus, where it activates
transcription of genes containing anti-oxidant response
elements (ARE) in their promoter region [26]. The func-
tions of genes transcribed by NRF2 association to ARE
include regulation of inflammation, migration of DC
and anti-oxidant defense enzymes, such as NADPH qui-
none oxidoreductase 1 (NQO1) and glutathione S-trans-
ferases (GST) [27,28], genes found in the Prediction
Signature. Furthermore, the NRF2/KEAP1/ARE pathway
has previously been described as activated in response
to skin sensitizers, inducing maturation of dendritic cells
[29].
Similarly, AHR is a transcription factor in the cytosol
that is activated by binding to ligands, which includes a
wide range of xenobiotic chemicals, such as halogenated
aromatic hydrocarbons, polyphenols and a number of
pharmaceuticals [30]. In the absence of a ligand, AHR is
bound by a complex of chaperon proteins, keeping it in
the cytosol. Upon ligand binding, AHR is translocated
to the nucleus, where it dimerizes with aryl hydrocarbon
receptor nuclear translocator (ARNT) [30]. The ARNT/
AHR heterodimer then binds to xenobiotic response ele-
ments (XRE) in promoter regions of target genes. The
typical target genes for XRE include enzymes for drug
metabolism, such as the cytochrome P450 (CYP) super-
family, as well as cytoprotective enzymes mediating
defense against oxidative stress, such as NQO1 [31].
Interestingly, while NQO1 is under control of both
NRF2 and AHR, with both ARE and XRE in the promo-
ter region, it has also been shown that AHR is among
the target genes for the activated NRF2 pathway and
vice versa [32]. Thus, a battery of protective enzymes
are induced in response to a variety of xenobiotics, pos-
sibly through a number of signaling pathways, ultimately
leading to the maturation of dendritic cells, as also indi-
cated by the present data. The protein ubiquitination
pathway is involved in degradation of short-lived or reg-
ulatory proteins involved in many cellular processes,
such as the cell cycle, cell proliferation, apoptosis, DNA
repair, transcription regulation, cell surface receptors
and ion channels regulation, and antigen presentation.
Of note, both NRF2 and AHR are in the resting cell
bound by proteins that are targeted for ubiquitination
upon ligand binding.
RXR is a nuclear receptor, with retinoic acid as the
most prominent natural ligand [33]. It has previously
been described as important for xenobiotics recognition
and glutathione homeostasis, with cytoprotective
enzymes as target genes [34,35].
TLR signaling is known to play a major role in dendri-
tic cell maturation, as they activate transcription of a
number of pro-inflammatory cytokines, chemokine-
receptors for homing to lymph nodes and co-stimula-
tory molecules [36-38]. While TLR6 and TLR9 are pre-
sent in our Prediction Signature, others have reported
TLR4 as a crucial mediator of contact allergy to nickel
[39]. As these receptors all signal through nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-B),
it is not surprising that different compounds activate
different receptors, considering the chemical diversity of
skin sensitizers, as discussed above.
Lastly, PKA signaling is a vastly versatile pathway acti-
vated by numerous stimuli, and, to the best of knowl-
edge, this pathway has not previously been reported in
association with skin sensitization. However, individual
s p e c i e so fC Y P sa r ek n o w nt ob ep h o s p h o r y l a t e db y
PKA, in response to elevated levels of cyclic adenosine
monophosphate (cAMP), triggered by xenobiotics. In
addition, cAMP levels influence the nuclear transloca-
tion of AHR, connecting these two pathways and their
impact on CYP activity [40].
Conclusion
In this paper, we have demonstrated the predictive
power of a genomic biomarker signature, which cor-
rectly classifies sensitizers and non-sensitizers. The bio-
marker signature was derived from the human DC-like
cell line MUTZ-3, which was challenged with a panel of
40 reference chemical compounds. The biomarker genes
were shown to be biologically relevant, as demonstrated
by their involvement in cytoprotective mechanisms and
pathways triggered by xenobiotic substances, supporting
their relevance as predictor genes for skin sensitization.
The findings reported in this paper might impact the
development of in vitro assays for assessment of skin
sensitization, which is crucial in order to replace the
animal models currently in use.
Methods
Chemicals
A panel of 40 chemical compounds, consisting of 20
sensitizers and 20 non-sensitizers were used for cell
stimulations. The sensitizers were 2,4-dinitrochloro-
benzene, cinnamaldehyde, resorcinol, oxazolone,
glyoxal, 2-mercaptobenzothiazole, eugenol, isoeugenol,
cinnamic alcohol, p-phenylendiamine, formaldehyde,
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aldehyde, potassium dichromate, penicillin G, kathon
CG (MCI/MI), 2-aminophenol, geraniol and 2-nitro-
1,4-phenylendiamine. The non-sensitizers were sodium
dodecyl sulphate, salicylic acid, phenol, glycerol, lactic
acid, chlorobenzene, p-hydrobenzoic acid, benzalde-
hyde, diethyl phtalate, octanoic acid, zinc sulphate, 4-
aminobenzoic acid, methyl salicylate, ethyl vanillin, iso-
propanol, dimethyl formamide, 1-butanol, potassium
permanganate, propylene glycol and tween 80
(Table 3). All chemicals were from Sigma-Aldrich, St.
Louis, MO, USA. Compounds were dissolved in either
dimethyl sulfoxide (DMSO) or distilled water. Prior to
stimulations, the cytotoxicity of all compounds was
monitored, using propidium iodide (PI) (BD Bios-
ciences, San Diego, CA) using protocol provided by
t h em a n u f a c t u r e r .T h er e l a t i v ev i a b i l i t yo fs t i m u l a t e d
cells was calculated as
Relativeviability =
fractionof viablestimulatedcells
fractionof viableunstimulatedcells
· 100
For toxic compounds, the concentration yielding 90%
relative viability (Rv90) was used. For non-toxic com-
pounds, a concentration of 500 μM was used. For non-
toxic compounds that were insoluble at 500 μMi n
medium, the highest soluble concentration was used.
For compounds dissolved in DMSO, the final concen-
tration of DMSO in each well was 0.1%. The vehicle
and concentrations used for each compound are listed
in Table 4.
Chemical exposure of the cells
The human myeloid leukemia-derived cell line MUTZ-3
(DSMZ, Braunschweig, Germany) was maintained in a-
MEM (Thermo Scientific Hyclone, Logan, UT) supple-
mented with 20% (volume/volume) fetal calf serum
(Invitrogen, Carlsbad, CA) and 40 ng/ml rhGM-CSF
(Bayer HealthCare Pharmaceuticals, Seattle, WA), as
described [10]. Cultures were maintained at 200.000
cells/ml during expansion, with a media change every 3-
4 days. No differentiating steps were performed. Instead,
the proliferating progenitor MUTZ-3 was used for sti-
mulations, as delivered by the supplier. Prior to each
experiment, the cells were immunophenotyped using
flow cytometry as a quality control. Cells were seeded in
6-well plates at 200.000 cells/ml. Stock solutions of each
compound were prepared in either DMSO or distilled
water, and were subsequently diluted so the in-well con-
centrations corresponded to the Rv90 value, and in-well
concentrations of DMSO were 0.1%. Cells were incu-
bated for 24 h at 37°C and 5% CO2. Thereafter, cells
were harvested and analyzed by flow cytometry. In
parallel, harvested cells were lysed in TRIzol reagent
(Invitrogen) and stored at -20°C until RNA extraction.
Stimulations with chemicals were performed in three
individual experiments, so that triplicates samples were
obtained.
Phenotypic analysis with flow cytometry
All cell surface staining and washing steps were per-
formed in PBS containing 1% BSA (w/v). Cells were
incubated with specific mouse mAbs for 15 min at 4°C.
The following mAbs were used for flow cytometry:
FITC-conjugated CD1a (DakoCytomation, Glostrup,
Denmark), CD34, CD86, and HLA-DR (BD Biosciences),
PE-conjugated CD14 (DakoCytomation), CD54 and
CD80 (BD Biosciences). Mouse IgG1, conjugated to
FITC or PE were used as isotype controls (BD Bios-
ciences) and PI was used to assess cell viability. FACS-
Diva software was used for data acquisition with
FACSCanto II instrument (BD Bioscience). 10,000
events were acquired and gates were set based on light
scatter properties to exclude debris and nonviable cells.
Further data analysis was performed using FCS Express
V3 (De Novo Software, Los Angeles, CA).
Preparation of cRNA and gene chip hybridization
R N Ai s o l a t i o na n dg e n ec h i ph y b r i d i z a t i o nw a sp e r -
formed as described [41]. Briefly, RNA from unstimu-
lated and chemical-stimulated MUTZ-3 cells, from
triplicate experiments, were extracted and analyzed. The
preparation of labeled sense DNA was performed
according to Affymetrix GeneChip™ Whole Transcript
(WT) Sense Target Labeling Assay (100 ng Total RNA
Labeling Protocol) using the recommended kits and
controls (Affymetrix, Santa Clara, CA). Hybridization,
washing and scanning of the Human Gene 1.0 ST
Arrays were performed according to the manufacturer’s
protocol (Affymetrix). The microarray data have been
deposited in the Array Express database http://www.ebi.
ac.uk/arrayexpress/ with accession number E-MTAB-
670.
Microarray data analysis and statistical methods
The microarray data were normalized and quality
checked with the RMA algorithm, using Affymetrix
Expression Console (Affymetrix). Genes that were sig-
nificantly regulated when comparing sensitizers with
non-sensitizers were identified using one-way
ANOVA, with false discovery rate (FDR) as a correc-
tion for multiple hypothesis testing. In order to
reduce the large number of identified significant
genes, we applied an algorithm developed in-house
for Backward Elimination of analytes [42]. With this
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(SVM) model [12] with leave-one out cross-validation,
with one analyte left out. This process is iterated until
each analyte has been left out once. For each iterative
step, a Kullback-Leibler divergence (KLD) is recorded,
yielding N KLDs, where N is the number of analytes.
The analyte that was left out when the smallest KLD
was observed is considered to provide the least infor-
mation in the data set. Thus, this analyte is eliminated
and the iterations proceed, this time with N-1 ana-
lytes. In this manner, the analytes are eliminated one
by one until a panel of markers remain that have
Table 3 List of reference chemicals used in assay development
Compound Abbreviation Potency LLNA HMT
1 HPTA
1
Sensitizers
2,4-Dinitrochlorobenzene DNCB Extreme [15] + [15]
Oxazolone OXA Extreme [15] + [15]
Potassium dichromate PD Extreme [14] + [14] + +
Kathon CG (MC/MCI) KCG Extreme [14,45] + [14,46]
Formaldehyde FA Strong [15] + [15] + +
2-Aminophenol 2AP Strong [46] + [47]
2-nitro-1,4-Phenylendiamine NPDA Strong [46] + [47]
p-Phenylendiamine PPD Strong [47] + [48] + +
Hexylcinnamic aldehyde HCA Moderate [15] + [15]
2-Hydroxyethyl acrylate 2HA Moderate [46] + [47] +
2-Mercaptobenzothiazole MBT Moderate [46] + [47] + +
Glyoxal GO Moderate [46] + [47] +
Cinnamaldehyde CALD Moderate [47] + [48] + +
Isoeugenol IEU Moderate [47] + [48] +
Ethylendiamine EDA Moderate [14] + [14]
Resorcinol RC Moderate [48] + [49] - +
Cinnamic alcohol CALC Weak [46] + [48]
Eugenol EU Weak [47] + [48] +
Penicillin G PEN G Weak [47] + [48] +
Geraniol GER Weak [14] + [14] - +
Non-sensitizers
1-Butanol BUT - [50]
4-Aminobenzoic acid PABA - [51] - +
Benzaldehyde BA - [52]
Chlorobenzene CB - [14]
Diethyl phthalate DP - [48]
Dimethyl formamide DF - [46]
Ethyl vanillin EV - [52]
Glycerol GLY - [48]
Isopropanol IP - [48]
Lactic acid LA - [14]
Methyl salicylate MS - [14] -
Octanoic acid OA - [53]
Propylene glycol PG - [51]
Phenol PHE - [53] -
p-Hydroxybenzoic acid HBA - [54]
Potassium permanganate PP -
Salicylic acid SA - [14] -
Sodium dodecyl sulphate SDS +
2 [14,53] -
Tween 80 T80 - [20] +
Zinc sulphate ZS +
2 [55]
List of sensitizers and non-sensitizers used in assay development. 1) HMT, Human Maximization Test; HPTA, Human Patch Test Allergen. Information is derived
from [17]. 2) False positives in LLNA.
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contribute with orthogonal information for the discri-
mination of skin sensitizers vs. non-sensitizers. The
selected biomarker profile of 200 transcripts were
designated the “Prediction Signature”.T h es c r i p t sf o r
Backwards Elimination and Support Vector Machines
were programmed for R [43], with the additional
package e1071 [44]. ANOVA analyses and visualiza-
tion of results with Principal Component Analysis
were performed in Qlucore Omics Explorer 2.1 (Qlu-
core AB, Lund, Sweden). Hierarchical clustering for
the heatmap was performed in R.
Table 4 Concentrations and vehicles used for each reference chemical
Compound Abbreviation Vehicle Max solubility
(μM)
Rv90
(μM)
Concentration
in culture (μM)
Sensitizers
2,4-Dinitrochlorobenzene DNCB DMSO - 4 4
Oxazolone OXA DMSO 250 - 250
Potassium dichromate PD Water 51.02 1.5 1.5
Kathon CG (MC/MCI)
1 KCG Water - 0.0035% 0.0035%
Formaldehyde FA Water - 80 80
2-Aminophenol 2AP DMSO - 100 100
2-nitro-1,4-Phenylendiamine NPDA DMSO - 300 300
p-Phenylendiamine PPD DMSO 566 75 75
Hexylcinnamic aldehyde HCA DMSO 32.34 - 32.24
2-Hydroxyethyl acrylate 2HA Water - 100 100
2-Mercaptobenzothiazole MBT DMSO 250 - 250
Glyoxal GO Water - 300 300
Cinnamaldehyde CALD Water - 120 120
Isoeugenol IEU DMSO 641 300 300
Ethylendiamine EDA Water - - 500
Resorcinol RC Water - - 500
Cinnamic alcohol CALC DMSO 500 - 500
Eugenol EU DMSO 649 300 300
Penicillin G PEN G Water - - 500
Geraniol GER DMSO - - 500
Non-sensitizers
1-Butanol BUT DMSO - - 500
4-Aminobenzoic acid PABA DMSO - - 500
Benzaldehyde BA DMSO 250 - 250
Chlorobenzene CB DMSO 98 - 98
Diethyl phthalate DP DMSO 50 - 50
Dimethyl formamide DF Water - - 500
Ethyl vanillin EV DMSO - - 500
Glycerol GLY Water - - 500
Isopropanol IP Water - - 500
Lactic acid LA Water - - 500
Methyl salicylate MS DMSO - - 500
Octanoic acid OA DMSO 504 - 500
Propylene glycol PG Water - - 500
Phenol PHE Water - - 500
p-Hydroxybenzoic acid HBA DMSO 250 - 250
Potassium permanganate PP Water 38 - 38
Salicylic acid SA DMSO - - 500
Sodium dodecyl sulphate SDS Water - 200 200
Tween 80 T80 DMSO - - 500
Zinc sulphate ZS Water 126 - 126
List of concentrations and vehicles used for each testing compound. 1) Kathon CG is a mixture of the compounds MC and MCI. The concentration of this mixture
is given in %.
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Page 17 of 19Interrogation of the method for identification of the
Prediction Signature
The data set was divided into a training set and a test
set, consisting of 70% and 30%, of the chemical com-
pounds, respectively. The division was performed ran-
domly, while maintaining the proportions of sensitizers
and non-sensitizers in each subset at the same ratio as
i nt h ec o m p l e t ed a t as e t .Ab i o m a r k e rs i g n a t u r ew a s
identified in the training set, using ANOVA filtering
and Backward Elimination, as described above. This test
signature was used to train an SVM, using the training
set, which was thereafter applied to predict the samples
of the test set. The process was repeated 20 times and
the distribution of the area under the Receiver Operat-
ing Characteristic (ROC) curve [45] was used as a mea-
surement of the performance of the model.
Assessment of biological functions of Prediction
Signature using pathway analysis
In order to investigate the biological functions the gene
profile of the 200 genes derived from the Backward
Elimination was analyzed, using the Ingenuity Pathway
Analysis software, IPA, (Ingenuity Systems, Inc. Moun-
tain View, USA). The gene profile was analyzed using
the ‘Build’ and ‘Path Explorer’ functions to build an
interactome of the core genes from the Prediction Sig-
nature together with connecting molecules, as suggested
by IPA. The molecules of the signature were connected
using the shortest known paths. In this process only
human data from primary cells, cell lines and epidermal
tissue was used. Public identifiers were used to map
genes in IPA. All molecules except for endogenous and
chemical drugs were allowed in the network and all
kinds of connections were allowed. Known ‘Functions’
and ‘Canonical Pathways’ from IPA were mapped to the
signature using the ‘Overlay’ function. The most densely
populated pathways and functions were reported. All
were significant, using the built in IPA statistical mea-
sures (p-values for functions and -log(p-values) for
pathways).
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